## Abstract Antibody reactivity to Epstein‐Barr virus (EBV)‐associated nuclear antigen (EBNA) was investigated by means of the anticomplement immunofluorescence technique on sera from patients with Hodgkin's disease (HD) and from appropriate controls. Antibody levels to other EBV‐determined antigen
Sensitive method to detect non-complement-fixing antibodies to Epstein-Barr virus nuclear antigen
✍ Scribed by H. Schmitz; D. Kampa; W. Heidenreich
- Publisher
- John Wiley and Sons
- Year
- 1975
- Tongue
- French
- Weight
- 327 KB
- Volume
- 16
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The anti‐complement immunofluorescence (ACIF) test was modified to detect non‐complement‐fixing antibodies to Epstein‐Barr (EB) virus nuclear antigen (EBNA). These EBNA antibodies belong to the immunoglobulin classes IgA and IgG. In our method anti‐human γ‐globulin (AHG) was bound to the EBNA antibodies before the complement was added. If only non‐complement‐fixing antibodies are present the complement can be fixed to the AHG. Within only a few weeks of the onset of infectious mononucleosis (IM) the non‐complement‐fixing EBNA antibodies reach high titers while the complement‐fixing antibodies (detected by the ACIF test) are not yet present. Anti‐EBNA‐IgM antibodies were not found in the IgM fractions of sera taken at different stages of IM.
📜 SIMILAR VOLUMES
## Abstract Greenland Eskimos comprise an ethnic group with one of the highest recorded incidence rates for nasopharyngeal carcinoma in the world. Sera from 625 Eskimos and 73 Danes (Caucasians) living in Greenland, as well as from 62 Danes living in Denmark, were tested for complement‐fixing antib
## Abstract Titration of anti‐complementary human sera may yield false negative or prozone reactions in anti‐complement immunofluorescence (ACIF) tests for antibodies to Epstein‐Barr virus‐associated nuclear antigen (EBNA) when the human complement (C') is added to the serum dilutions prior to char
IgG and IgA antibodies to Epstein-Barr virus (EBV) membrane antigen (MA) were detected in sera from 96 NPC patients and normal individuals by the indirect immunofluorescence test. For MA/IgG antibody, 100% of NPC patients were positive with a GMT of 1:439.7 and 97.9% of normal individuals were posit